- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Janelle Hart | Authors
Immunotherapy Continues to Influence Perioperative Bladder Cancer Management
March 18, 2022
At the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Adrenocortical Carcinoma at Low/Intermediate Recurrence Risk Does Not Benefit From Postoperative Adjuvant Mitotane
February 21, 2022
Efficacy of adjuvant mitotane for patients with adrenocortical carcinoma following surgery was presented at 2022 ASCO GU.
Favorable Detection Rates Reported With 18F-rhPSMA-7.3 for Recurrence of Prostate Cancer
February 18, 2022
Data reported from the phase 3 SPOTLIGHT trial of the novel theranostic 18F-rhPSMA-7.3 at 2022 ASCO GU show “excellent image quality” for prostate cancer recurrence detection, according to expert.
Antitumor Activity Continues With Olaparib Plus Pembrolizumab Combo in mCRPC
September 15, 2021
Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.